Academia Sinica

National Taiwan University

Tripod Nano Technology Corporation

Tripod Technology Corporation

Other

National Yang Ming Chiao Tung University

National Science Council

Council of Agriculture, Executive Yuan

Allied Industrial Corp., Ltd.

Jim-min Fang

Ting-jen R. Cheng

Kung-cheng Liu

Yih-shyun E. Cheng

Jia-tsrong Jan

Wong, Chi-huey

Jim-Min Fang

Chi-Huey Wong

Jiun-Jie Shie

Yih-Shyun Edmond Cheng

Chih-Cheng Chen

Ting-Jen Rachel Cheng

Yun-Lian Lin

Yijuang Chern

Chun-Lun Chiu Chiu

Lin Lu

Cheng-Ding Wang

Kuei-Sheng Fan

Nai-Kuei Huang

Jung-Hsin Lin

Cheng-Han Lee

Jia-Tsrong Jan

Yih-Shyun Edmund Cheng

Jen-Yao Chang

Ting-Rong Chern

Jhih-Bin Chen

Han-Wu Yen

Jung-Hsing Lin

Tzu-Tang Wei

Chun-Jung Lin

Ching-Chow Chen

Chi-Jiun Peng

Chen-Hsiang Wang

Chih-Kung Lee

Chung-Yi Wu

Pan-Chyr Yang

Chii-Wann Lin

Chia-Ching Lin

Ling Lu

Wen-Bin Yang

Chia-Chi Chang

Rea-Min Chu

Szu-Hua Pan

Zee-Fen Chang

Tsung-Liang Chuang

Shi-Ming Lin

Chia-I Lin

Ching-Ho Wang

Benjamin Pang-Hsien Tu

Shean-Jeng Jong

Charng-Sheng Tsai

Ling-Wei Li

Hao-Chan Hsu

Zee Fen Chang

Chun-Mei Hu

Chia-Yi Lin

Ming-Tyng Yeh

Hung-Li Wang

Yves Shang-Yi Hsieh

Cheng Chien

Chamg-Sheng Tsai

Chih-Chien Lin

Kung-Cheng Liu

Hao-Yu Wen

Hui-Ming Yu

Jheng-Long Lee

Wei-Nan Chen

Rong-Huay Juang

Chung-Jung Hung

Hsin-Chang Huang

Teng-Chieh Hsu

Meng-Hsiu Chih

Shao-Tzu Tang

Ta-Wei Chang

Chao-Tsen Chen

Chia-Ching John Lin

Yih-Shyun E Cheng

Ting-Jen R Cheng

Compounds for use in prevention and/or treatment of pain are disclosed. The compounds are derived by conjugation of N-(4-hydroxybenzyl)adenosine and analogous compounds with amino acids or peptides. In one embodiment of the invention, the compound is 5'-glycylcarbonyl-N-(4-hydroxybenzyl)adenosine (I-a1). In another embodiment of the invention, the compound is 5′-deoxy-5′-(N′-glycylureido)-N-(4-hydroxybenzyl)adenosine (I-d1). Also disclosed are methods of making and using the same.

Compound with analgesic effect for use in prevention and treatment of pain

Compounds for use in prevention and/or treatment of pain are disclosed. The compounds are derived by conjugation of N-(4-hydroxybenzyl)adenosine and analogous compounds with amino acids or peptides. In one embodiment of the invention, the compound is 5'-O-(glycine-N-carbonyl-N-(4-hydroxybenzyl)adenosine (I-a1). In another embodiment of the invention, the compound is 5-deoxy-5&#x2032;-(glycine-N-amido)-N6-(4-hydroxybenzyl)adenosine (I-d1). Also disclosed are methods of making and using the same.

Provided is a method of making colloidal selenium nanoparticles. The method includes the steps as follows: Step (A): providing a reducing agent and an aqueous solution containing a selenium precursor; Step (B): mixing the aqueous solution containing the selenium precursor and the reducing agent to form a mixture solution in a reaction vessel and heating the mixture solution to undergo a reduction reaction and produce a composition containing selenium nanoparticles, residues and a gas, and guiding the gas out of the reaction vessel, wherein an amount of the residues is less than 20% by volume of the mixture solution; and Step (C): dispersing the selenium nanoparticles with a medium to obtain the colloidal selenium nanoparticles. The method has advantages of simplicity, safety, time-effectiveness, cost-effectiveness, high yield and eco-friendliness.

Method of making colloidal selenium nanoparticles

Provided is a method of making colloidal platinum nanoparticles. The method includes three consecutive steps: dissolving platinum powders by a halogen-containing oxidizing agent in HCl to obtain an inorganic platinum solution containing an inorganic platinum compound; adding a reducing agent into the same reaction vessel to form a mixture solution and heating the mixture solution to undergo a reduction reaction and produce a composition containing platinum nanoparticles, residues and a gas, and guiding the gas out of the reaction vessel, wherein the amount of the residues is less than 15% by volume of the mixture solution; and adding a medium into the same reaction vessel to disperse the platinum nanoparticles to obtain colloidal platinum nanoparticles. The method is simple, safe, time-effective, cost-effective, and has the advantage of high yield.

Method of making colloidal platinum nanoparticles

Provided is a method of making an inorganic platinum compound. The method includes the steps of: Step (A): providing a platinum material and a halogen-containing oxidizing agent; and Step (B): treating the platinum material with the halogen-containing oxidizing agent in a hydrochloric acid aqueous solution to obtain the inorganic platinum compound, including chloroplatinic acid or chloroplatinate salt; wherein the halogen-containing oxidizing agent excludes chlorine gas. The method of making an inorganic platinum compound is simple, safe, time-effective, cost-effective, and environment-friendly, and has the advantage of high yield.

Method of making an inorganic platinum compound

The present disclosure provides compounds of Formulas (I') and (I), and pharmaceutically acceptable salts thereof. The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, and uses thereof for treating proliferative diseases. 

Purine compounds possessing anticancer activity

The present invention provides therapeutic agents for preventing and treating neurodegenerative diseases. These agents synergistically target both the adenosine Areceptor (AR) and the equilibrative nucleoside transporter 1 (ENT1).

[object Object]

Compounds for use in prevention and treatment of neurodegenerative disease and pain are disclosed. In one embodiment of the invention, the compound is selected from the group consisting of N-[(3-halothien-2-yl)methyl]adenosine, N-[(4-halothien-2-yl)methyl]adenosine, and N-[(5-halothien-2-yl)methyl]adenosine. In another embodiment of the invention, the compound is selected from the group consisting of N-[(2-bromothien-3-yl)methyl]adenosine, N-[(4-bromothien-3-yl)methyl]adenosine, N-[(5-bromothien-3-yl)methyl]adenosine N-[(2-chlorothien-3-yl)methyl]adenosine, N-[(4-chlorothien-3-yl)methyl]adenosine, and N-[(5-chlorothien-3-yl)methyl]adenosine. Also disclosed are methods of making and using the same.

Compounds for use in prevention and treatment of neurodegenerative diseases and pain

Provided herein are compounds for use as sialidase inhibitors, including alkynyl-3-fluorosialyl fluoride. The compounds, which include the compound DFSA, function by trapping a 3-fluorosialylenzyme intermediate (reporter-inhibitor-enzyme conjugate). These compounds can be conjugated with a detectable tagging moiety for isolation and identification of sialidases.

Cell-permeable probes for identification and imaging of sialidases

Novel dual-targeted, bifunctional anti-influenza drugs formed by conjugation with anti-inflammatory agents are disclosed. Exemplary drugs according to the invention include caffeic acid (CA)-bearing zanamivir (ZA) conjugates ZA-7-CA (1), ZA-7-CA-amide (7) and ZA-7-Nap (43) for simultaneous inhibition of influenza virus neuraminidase and suppression of proinflammatory cytokines. Synthetic methods for preparation of these enhanced anti-influenza conjugate drugs are provided. The synthetic bifunctional ZA conjugates act synergistically towards protection of mice lethally infected by H1N1 or H5N1 influenza viruses. The efficacy of ZA-7-CA, ZA-7-CA-amide and ZA-7-Nap conjugates is much greater than the combination therapy of ZA with anti-inflammatory agents.

Enhanced anti-influenza agents conjugated with anti-inflammatory activity

Methods for treating pain such as fibromyalgia, comprising administering to a subject in need thereof an effective amount of an adenosine analog, wherein the adenosine analog may be a compound of Formula (I): 

Methods and compositions for treating pain

Provided are azido-BODIPY compounds of formula (I), cyclooctyne-based fluorogenic probes of formula (IV), and activity-based probes of formula (VI). These compounds undergo azide-alkyne cycloadditions (AAC) with to form triazolyl products. The provided compounds are useful for detection and imaging of alkyne-, or azide-containing molecules. Methods for detection and imaging biomolecules using compounds of the present disclosure are disclosed.

Reactive labelling compounds and uses thereof

Provided is a method of making colloidal metal nanoparticles. The method includes the steps of: mixing a metal aqueous solution and a reducing agent to form a mixture solution in a reaction tank; heating the mixture solution and undergoing a reduction reaction to produce a composition containing metal nanoparticles, residues and gas, wherein the amount of the residues is less than 20% by volume of the mixture solution, and guiding the gas out of the reaction tank; dispersing the metal nanoparticles with a medium to obtain colloidal metal nanoparticles. By separating the reduction reaction step and the dispersion step, the method of making colloidal metal nanoparticles is simple, safe, time-effective, cost-effective, and has the advantage of high yield.

Method of making colloidal metal nanoparticles

A method of making the inorganic gold compound, such as tetrachloroauric acid, sodium tetrachloroaurate, potassium tetrachloroaurate, sodium tetracyanoaurate, and potassium tetracyanoaurate, includes the step of: treating gold with a halogen-containing oxidizing agent in a hydrochloric acid to obtain the inorganic gold compound, wherein the halogen-containing oxidizing agent excludes chlorine gas. The method of making the inorganic gold compound is simple, safe, time-effective, cost-effective, and environment-friendly, and has the advantage of high yield.

Method of making inorganic gold compound

Provided herein are novel irreversible sialidase inhibitors. These compounds can be conjugated with a detectable tagging moiety such as azide-annexed biotin via CuAAC for isolation and identification of sialidases. The provided compounds and the corresponding detectable conjugates are useful for detecting sialidase-containing pathogens and imaging in situ sialidase activities under physiological conditions.

Growing community of inventors

Taipei, Taiwan

Jim-Min Fang